Latest news with #Attruby
Yahoo
a day ago
- Business
- Yahoo
BridgeBio price target raised to $42 from $37 at BMO Capital
BMO Capital raised the firm's price target on BridgeBio (BBIO) to $42 from $37 and keeps a Market Perform rating on the shares. The firm anticipates Attruby's U.S. sales in Q2 to be $77M-$89M, reflecting 110%-145% sequential growth and 20%-40% revenues above consensus, helping to drive 5%-15% upside in BridgeBio shares, the analyst tells investors in a research note. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on BBIO: Disclaimer & DisclosureReport an Issue Hold Rating for BridgeBio Pharma Amid Competitive Pressures and Uncertain Long-term Outlook BridgeBio Pharma: Strong Launch Momentum and Promising Pipeline Drive Buy Rating BridgeBio presents data from ATTRibute-CM BridgeBio Pharma: Promising Outlook with Strong Execution and Growth Potential BridgeBio announces first participant dosed with acoramidis in ACT-EARLY Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
27-05-2025
- Entertainment
- Wall Street Journal
Ask Your Doctor About the Mute Button
Not long ago I acquired a new television set. On it I watch lots of sports, too much news, older movies, PBS mysteries, and the occasional concert or documentary. I worry, though, that the set might soon go on the fritz because I so often press the mute button on its remote. What I mute—turning my head away from the television screen—is commercials, specifically those having to do with health, hospitals, clinics and innumerable pharmaceuticals from Attruby to Zyrtec. I recall reading that eight minutes of every half-hour of television are given over to commercials. I'm not against commercials per se. I am enough of a capitalist to recognize that someone must pay for my entertainment. OK, show all the beer and car ads you like, but the predominance of commercials about health—really, about failing health—is quite another matter.
Yahoo
14-05-2025
- Business
- Yahoo
Bluebird extends deal deadline; Affimed files for insolvency
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Bluebird bio and Affimed, as well as updates from Cytokinetics, BridgeBio Pharma and Acelyrin that you may have missed. Carlyle and SK Capital Partners, two investment firms attempting to buy Bluebird bio, have amended their offer to give Bluebird shareholders a choice of payouts. Holders of Bluebird stock can either receive $3 per share plus rights to $6.84 more if a certain sales milestone is achieved — Carlyle and SK Capital's original bid — or $5 per share. Shareholders previously had a deadline of May 12 to tender their stock to the original deal, but now have until May 29 to do so. Bluebird's board is in favor of accepting Carlyle and SK Capital's offer, warning investors in a statement Wednesday that, absent a deal, the company is at 'significant risk' of default. — Ned Pagliarulo Cancer drug developer Affimed has filed for 'insolvency,' warning investors Tuesday that there is 'substantial doubt' the company can sustain itself. As a result of the filing, Affimed shares will be suspended from trading on the Nasdaq stock exchange beginning May 20. The company has been talking with 'potential investors and partners' about deals or other ways in which it might raise capital, but has so far been unsuccessful. Affimed, which has three drugs in clinical testing, last reported cash holdings of 24 million euros as of Sept. 30, 2024. — Ned Pagliarulo Cytokinetics on Tuesday said its experimental drug aficamten outperformed beta blockers in a Phase 3 study of people with obstructive hypertrophic cardiomyopathy. U.S. regulators are already reviewing aficamten's use in the inherited heart condition, with an approval decision now expected by late December after a recent delay. The latest results, though generally expected by investors, could help boost its case with physicians and insurers, wrote RBC Capital Markets analyst Brian Abrahams. If approved, aficamten would compete for market share with Bristol Myers Squibb's Camzyos, which booked $602 million in sales last year. — Ben Fidler BridgeBio Pharma has begun dosing patients in a first-of-its-kind Phase 3 trial testing whether its drug, Attruby, can prevent or delay the onset of transthyretin amyloidosis in people more likely to inherit it. The trial, ACT-EARLY, will evaluate Attruby as a prophylactic treatment in carriers of a disease-causing variant of the TTR gene that's implicated in the hereditary form of the condition. Attruby is one of three marketed drugs that can slow progression of a type of transthyretin amyloidosis that affects the heart. No medicines have been proven to prevent the disease, however. — Ben Fidler Shareholders in Acelyrin and Alumis voted Tuesday to combine the two biotechnology companies, ending a twisting merger saga that featured an unsolicited bid from an entity controlled by and a push from to force Acelyrin to liquidate its assets and return cash to its stockholders. Since announcing the planned combination, Alumis has tweaked the terms of the deal, saying its shareholders would own 52% of the new company, while Acelyrin's would hold 48%. The merger is now set to close in the second quarter of 2025. — Gwendolyn Wu Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday
We recently published an article titled . In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other stocks. Wall Street's main indices finished mixed on Tuesday, as investors digested the country's latest inflation figures, which came out lower than expected. On Tuesday, the Labor Department reported that the Consumer Price Index for April rose by only 0.2 percent last month, bringing the annual inflation rate to 2.3 percent, versus the 2.4 percent in March. It was the lowest annual rate since February 2021. Only the S&P 500 and the tech-heavy Nasdaq registered gains among all major indices, up by 0.72 percent and 1.61 percent, respectively. The Dow Jones, on the other hand, was down by 0.64 percent. Beyond the main indices, 10 firms lagged in performance amid negative news, sparking sell-offs. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A team of scientists in white lab coats reviewing lab results in a research facility. BridgeBio Pharma, Inc. (NASDAQ:BBIO) saw its share price decline by 6.78 percent on Tuesday to finish at $33.26 each following President Donald Trump's new executive order directing drugmakers to lower the prices of drugs. BridgeBio Pharma, Inc. (NASDAQ:BBIO), a biotechnology company, dropped alongside its counterparts in the healthcare sector as investors feared that the new order would dent the profits and margins of drugmakers and retailers. In recent news, BridgeBio Pharma, Inc. (NASDAQ:BBIO) widened its net loss by 371 percent to $169.6 million in the first quarter of the year from $36 million in the same period a year earlier, while revenues fell by 45 percent to $116 million from $211 million year-on-year. Of the total revenue, $36.7 million was attributed to Attruby. Meanwhile, the company was gaining strong traction for its heart treatment, Attruby, having recorded 2,072 prescriptions written by 756 prescribers as of April 25. Overall BBIO ranks 8th on our list of Tuesday's worst performers. While we acknowledge the potential of BBIO as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BBIO but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday
We recently published an article titled . In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other stocks. Wall Street's main indices finished mixed on Tuesday, as investors digested the country's latest inflation figures, which came out lower than expected. On Tuesday, the Labor Department reported that the Consumer Price Index for April rose by only 0.2 percent last month, bringing the annual inflation rate to 2.3 percent, versus the 2.4 percent in March. It was the lowest annual rate since February 2021. Only the S&P 500 and the tech-heavy Nasdaq registered gains among all major indices, up by 0.72 percent and 1.61 percent, respectively. The Dow Jones, on the other hand, was down by 0.64 percent. Beyond the main indices, 10 firms lagged in performance amid negative news, sparking sell-offs. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A team of scientists in white lab coats reviewing lab results in a research facility. BridgeBio Pharma, Inc. (NASDAQ:BBIO) saw its share price decline by 6.78 percent on Tuesday to finish at $33.26 each following President Donald Trump's new executive order directing drugmakers to lower the prices of drugs. BridgeBio Pharma, Inc. (NASDAQ:BBIO), a biotechnology company, dropped alongside its counterparts in the healthcare sector as investors feared that the new order would dent the profits and margins of drugmakers and retailers. In recent news, BridgeBio Pharma, Inc. (NASDAQ:BBIO) widened its net loss by 371 percent to $169.6 million in the first quarter of the year from $36 million in the same period a year earlier, while revenues fell by 45 percent to $116 million from $211 million year-on-year. Of the total revenue, $36.7 million was attributed to Attruby. Meanwhile, the company was gaining strong traction for its heart treatment, Attruby, having recorded 2,072 prescriptions written by 756 prescribers as of April 25. Overall BBIO ranks 8th on our list of Tuesday's worst performers. While we acknowledge the potential of BBIO as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BBIO but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
